Table 3 Cross-correlations
From: Predictors of loss due to pharmaceutical fraud: evidence from the U.S.
Cost | Age | Male | White | Collusion | Duration | US_public | In_biz | N_employees | Revenue | Misbranding | Counterfeit | Off_label_use | Pharm_fraud_act | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cost | 1 | |||||||||||||
Age | − 0.0281 | 1 | ||||||||||||
Male | 0.0776 | − 0.0364 | 1 | |||||||||||
White | 0.0893 | 0.1619 | − 0.0800 | 1 | ||||||||||
Collusion | − 0.1217 | 0.1436 | − 0.1466 | − 0.0018 | 1 | |||||||||
Duration | 0.1927 | − 0.1328 | 0.2210 | − 0.1244 | − 0.1268 | 1 | ||||||||
US_public | 0.4153* | − 0.0562 | 0.0994 | 0.0656 | − 0.1607 | 0.2642 | 1 | |||||||
In_biz | 0.4884* | 0.2414 | − 0.1115 | 0.1694 | − 0.1706 | 0.0455 | 0.2112 | 1 | ||||||
N_employees | 0.1464 | − 0.1126 | 0.0508 | − 0.1531 | − 0.1274 | 0.3868* | 0.5079* | 0.0935 | 1 | |||||
Annual revenue | 0.0549 | 0.0301 | 0.0725 | − 0.0639 | 0.5697* | − 0.0202 | − 0.0174 | 0.0668 | 1 | |||||
Misbranding | − 0.1774 | 0.0211 | 0.1696 | − 0.1451 | − 0.0173 | 0.2679 | − 0.0619 | − 0.1354 | − 0.1029 | 0.1734 | 1 | |||
Counterfeiture | − 0.0422 | − 0.0374 | − 0.2233 | − 0.2308 | 0.0394 | 0.1683 | − 0.1706 | 0.0630 | − 0.0219 | 0.6844* | − 0.1121 | 1 | ||
Off_label_use | 0.3274* | 0.1014 | 0.1214 | 0.0917 | − 0.0050 | − 0.1281 | 0.3366* | 0.1968 | 0.2459 | − 0.1107 | − 0.5984* | − 0.2271 | 1 | |
Pharm_fraud_act | − 0.1355 | − 0.1528 | − 0.2012 | 0.1409 | − 0.0129 | − 0.2280 | − 0.2132 | − 0.1448 | − 0.1571 | − 0.0805 | − 0.2969* | − 0.1481 | − 0.2843* | 1 |